Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26244
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWijns, William-
dc.contributor.authorVROLIX, Mathias-
dc.contributor.authorVerheye, Stefan-
dc.contributor.authorSchoors, Danny-
dc.contributor.authorSlagboom, Ton-
dc.contributor.authorGosselink, Marcel-
dc.contributor.authorBENIT, Edouard-
dc.contributor.authorKandzari, David-
dc.contributor.authorDonohoe, Dennis-
dc.contributor.authorOrmiston, John-
dc.date.accessioned2018-06-29T08:32:34Z-
dc.date.available2018-06-29T08:32:34Z-
dc.date.issued2018-
dc.identifier.citationEUROINTERVENTION, 13(18), p. E2147-E2151-
dc.identifier.issn1774-024X-
dc.identifier.urihttp://hdl.handle.net/1942/26244-
dc.description.abstractAims: The aim of this study was to evaluate the five-year clinical results of a sirolimus-eluting stent (MiStent SES) with a bioabsorbable coating designed for sustained drug delivery during and after rapid polymer dissolution. Methods and results: The five-year results from the DESSOLVE I and II trials including major adverse cardiac events (MACE), target lesion failure (TLF), target vessel failure (TVF), and stent thrombosis (ST) at five-year follow-up are reported. In DESSOLVE I, 10.3% of patients receiving the MiStent SES (3/29) had a MACE event up to five years without TLF. In DESSOLVE II, 15.1% of patients in the MiStent group (18/119) had a five-year MACE event compared to 22.0% of patients in the Endeavor group (p= 0.295). TLF was 9.2% in the MiStent group and 8.5% in the Endeavor group (p= 1.00). TVF was 10.1% for MiStent versus 15.3% for Endeavor (p= 0.331). Up to five-year follow-up, the MiStent SES has continued to demonstrate low rates of TLR across DESSOLVE I (0.0%) and DESSOLVE II (3.4%). No ST was reported with the MiStent up to five years in the DESSOLVE I trial. In DESSOLVE II, definite or probable ST was 0.0% with MiStent and 1.7% with Endeavor up to five years. Conclusions: The MiStent SES demonstrated long-term safety and effectiveness with low rates of fiveyear MACE, TLF, and TVF across these two clinical trials.-
dc.description.sponsorshipThis trial is sponsored by Micell Technologies, Durham, NC, USA.-
dc.language.isoen-
dc.subject.otherclinical research; clinical trials; drug-eluting stent; multiple vessel disease; single vessel disease-
dc.titleLong-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials-
dc.typeJournal Contribution-
dc.identifier.epageE2151-
dc.identifier.issue18-
dc.identifier.spageE2147-
dc.identifier.volume13-
local.bibliographicCitation.jcatA1-
dc.description.notesWijns, W (reprint author), Natl Univ Ireland Galway, Lambe Inst Translat Med, Floor 2,Univ Rd, Galway H91 TK33, Ireland. William.Wyns@nuigalway.ie-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.classdsPublValOverrule/author_version_not_expected-
local.classdsPublValOverrule/internal_author_not_expected-
local.classIncludeIn-ExcludeFrom-List/ExcludeFromFRIS-
dc.identifier.doi10.4244/EIJ-D-17-00230-
dc.identifier.isi000430649300013-
item.accessRightsClosed Access-
item.contributorWijns, William-
item.contributorVROLIX, Mathias-
item.contributorVerheye, Stefan-
item.contributorSchoors, Danny-
item.contributorSlagboom, Ton-
item.contributorGosselink, Marcel-
item.contributorBENIT, Edouard-
item.contributorKandzari, David-
item.contributorDonohoe, Dennis-
item.contributorOrmiston, John-
item.fullcitationWijns, William; VROLIX, Mathias; Verheye, Stefan; Schoors, Danny; Slagboom, Ton; Gosselink, Marcel; BENIT, Edouard; Kandzari, David; Donohoe, Dennis & Ormiston, John (2018) Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials. In: EUROINTERVENTION, 13(18), p. E2147-E2151.-
item.fulltextNo Fulltext-
crisitem.journal.issn1774-024X-
crisitem.journal.eissn1969-6213-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.